Many disease‑causing proteins lack suitable binding pockets for traditional small‑molecule inhibitors, leaving conditions such as certain hematologic cancers, solid tumors, and neurodegenerative diseases without effective pharmacologic options. ” The platform combines a library of chemically diverse ligands with a degrader scaffold that recruits cellular ubiquitin‑proteasome machinery, causing selective proteasomal degradation of the target protein. By varying the ligand and linker components, the system can be rapidly re‑configured to address new disease targets across hematologic, oncology, and brain‑disease indications.
Funding
Funding not disclosed
Founders
Product
Problem
Many disease‑causing proteins lack suitable binding pockets for traditional small‑molecule inhibitors, leaving conditions such as certain hematologic cancers, solid tumors, and neurodegenerative diseases without effective pharmacologic options.
Solution
Ten30bio has built a modular small‑molecule platform that enables the design of protein‑degrading therapeutics, also known as molecular degraders, to target proteins previously considered “undruggable.” The platform combines a library of chemically diverse ligands with a degrader scaffold that recruits cellular ubiquitin‑proteasome machinery, causing selective proteasomal degradation of the target protein. By varying the ligand and linker components, the system can be rapidly re‑configured to address new disease targets across hematologic, oncology, and brain‑disease indications. The approach aims to generate next‑generation therapeutics that achieve higher potency and durability than conventional inhibition, while maintaining drug‑like properties suitable for clinical development.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to develop therapies for targets that are not amenable to conventional inhibition, particularly in hematology, oncology, and central‑nervous‑system disease areas.
Features
- Modular chemistry library allowing rapid assembly of ligand‑linker‑E3 ligase recruiter combinations
- High‑throughput screening workflow to identify degraders that induce target protein ubiquitination and proteasomal clearance
- Optimized small‑molecule scaffolds designed for oral bioavailability and blood‑brain barrier penetration
- Integrated structure‑activity relationship (SAR) analytics to fine‑tune potency, selectivity, and pharmacokinetics
- Platform supports multiple E3 ligase recruitment strategies to expand target space